Le Lézard
Classified in: Health
Subjects: TRI, FDA, MAT

How to Reduce Your Regulatory Risk in the Renaissance of Hemp-Derived "Ceutical" Products, Upcoming Webinar Hosted by Xtalks


TORONTO, Sept. 11, 2019 /PRNewswire-PRWeb/ -- With recent regulatory changes to state and national laws, cannabis is undergoing a period of rediscovery and attraction from big pharma, nutraceutical manufacturers, food companies, and retailers.

Chronic CBD users represent 7 percent of the American population, and North American use rates are expected to rise as access to hemp-derived CBD food products increases. In preclinical studies, CBD shows potential therapeutic efficacy against a diverse array of clinical conditions, yet there are major research gaps in our understanding of CBD efficacy for most medical conditions touted in marketing.

Food and dietary supplement contract manufacturers and own label distributors are responsible for knowing the No Observed Adverse Effect Level (NOAEL) which can be learned from clinical studies of the test article. The road to regulatory approval by regulators such as the US Food and Drug Administration (FDA) and Health Canada features safety assessments from preclinical rodent testing, clinical trials, New Dietary Ingredient notifications (NDINs), licensing agreements and more.

In this free webinar, experts from KGK Science will help regulatory personnel, senior level executives, contract manufacturers and food toxicologists navigate this complicated process. The live session with Chief Science Officer Mal Evans, DVM, PhD and Chief Regulatory Officer Corey Hilmas, MD, PhD will take place on Wednesday, September 25, 2019 at 1pm EDT. The presentation will be followed by a live Q&A period.

Specific learning objectives include:

For more information or to register for this free event, visit How to Reduce Your Regulatory Risk in the Renaissance of Hemp-Derived "Ceutical" Products.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private and academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends, and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

 

SOURCE Xtalks


These press releases may also interest you

at 03:00
MedAlliance has announced enrollment of the first patient in its study of SELUTION SLRtm 014 DEB for the treatment of In-Stent Restenosis (ISR). This is the first DEB accepted by the FDA for its 'Breakthrough Program'. The SELUTION SLR (Sustained...

at 03:00
Uniform Advantage (UA), a multi-channel retailer of medical uniforms for medical and hospitality industries, develops an innovative exclusive scrub collection for men and women, focused on comfort, durability and functionality. "We designed Movement...

10 jui 2020
Johns Hopkins University filed suit in federal court Friday in an effort to stop a Trump administration rule change that would severely impact nearly 5,000 international students at the university. The decision to abruptly rescind accommodations for...

10 jui 2020
Worries and anxiety about COVID-19 and its impact can be overwhelming for people with spinal cord disease or injury and social distancing makes it even more challenging. "For folks with a spinal cord injury, the COVID-19 pandemic can induce symptoms...

10 jui 2020
Lincoln International is pleased to announce that The Araz Group, Inc. (d/b/a HealthEZ), a leading independent third-party administrator (TPA) of self-funded medical plans, has received an investment from Abry Partners LP, a private investment firm...

10 jui 2020
MPX International Corporation ("MPX International", "MPXI" or the "Corporation") today reports financial results for its second quarter, the three and six month period ended March 31, 2020. All figures are presented...



News published on 11 september 2019 at 09:00 and distributed by: